易瑞生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	224.0M	254.0M	687.0M	598.0M	258.0M
Revenue Growth %	-11.8%	-63.0%	14.9%	131.8%	--
Total Revenue	224.0M	254.0M	687.0M	598.0M	258.0M
Cost Of Revenue	65.9M	127.0M	299.0M	170.0M	63.7M
+Gross Profit	158.1M	127.0M	388.0M	428.0M	194.3M
Gross Margin %	70.6%	50.0%	56.5%	71.6%	75.3%
Total Operating Cost	220.0M	392.0M	608.0M	354.0M	203.0M
Selling Expenses	45.0M	56.8M	58.9M	48.1M	32.2M
Admin Expenses	50.3M	94.4M	92.3M	52.0M	38.7M
Rd Expenses	40.5M	53.1M	111.0M	72.4M	40.5M
Finance Expenses	7.9M	-2.8M	-8.5M	5.0M	10.9M
+Operating Income	21.0M	-175.0M	98.1M	268.0M	75.1M
Operating Margin %	9.4%	-68.9%	14.3%	44.8%	29.1%
Non Operating Income	356,600	975,200	170,600	111,600	27,800
Non Operating Expenses	1.6M	3.5M	3.4M	349,100	1.2M
Investment Income	-5.8M	-54.1M	2.7M	4.5M	8.8M
Fair Value Change Income	1.9M	28,000	--	5.2M	--
Asset Disposal Income	2.3M	2.8M	1.4M	--	--
Asset Impairment Loss	2.1M	56.4M	48.3M	1.4M	13.6M
Other Income	18.9M	14.3M	14.8M	15.6M	10.9M
Income Before Tax	19.7M	-178.0M	94.9M	268.0M	73.9M
Income Tax	3.1M	7.2M	12.2M	31.6M	8.5M
+Net Income	16.6M	-185.0M	82.7M	236.0M	65.4M
Net Margin %	7.4%	-72.8%	12.0%	39.5%	25.4%
Net Income Attributable	17.1M	-185.0M	83.0M	237.0M	65.4M
Minority Interest	-497,100	-75,600	-301,700	-37,400	4,300
Eps Basic	0.04	-0.46	0.21	0.60	0.18
Eps Diluted	0.04	-0.46	0.21	0.60	0.18

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	293.0M	482.0M	247.0M	342.0M	379.0M
Trading Financial Assets	303.0M	120.0M	--	340.0M	--
Accounts Receivable	94.1M	76.1M	83.9M	97.1M	62.3M
Notes Receivable	50,000	--	--	150,000	318,700
Notes And Accounts Receivable	94.1M	76.1M	83.9M	97.2M	62.6M
Prepayments	4.9M	6.0M	13.8M	16.6M	9.3M
Inventory	40.4M	31.5M	101.0M	93.9M	61.6M
Total Current Assets	752.0M	738.0M	674.0M	898.0M	526.0M
Long Term Equity Investment	101.0M	145.0M	196.0M	21.9M	3.5M
Fixed Assets	--	57.1M	84.0M	52.6M	44.9M
Fixed Assets Total	363.0M	57.1M	84.0M	52.6M	44.9M
Construction In Progress	--	357.0M	191.0M	51.3M	--
Construction In Progress Total	200.0M	357.0M	191.0M	51.3M	--
Intangible Assets	39.2M	41.4M	42.4M	42.6M	44.1M
Long Term Deferred Expenses	1.7M	1.9M	14.3M	11.4M	14.7M
Total Non Current Assets	706.0M	619.0M	608.0M	255.0M	127.0M
Total Assets	1.5B	1.4B	1.3B	1.2B	653.0M
Accounts Payable	58.8M	77.4M	65.1M	55.7M	14.6M
Advance Receipts	109,600	--	--	--	--
Contract Liabilities	25.0M	18.6M	66.6M	27.6M	36.0M
Total Current Liabilities	152.0M	137.0M	200.0M	157.0M	78.1M
Long Term Borrowings	163.0M	100.0M	56.3M	--	--
Total Non Current Liabilities	435.0M	371.0M	118.0M	49.3M	25.8M
Total Liabilities	587.0M	508.0M	318.0M	206.0M	104.0M
Paid In Capital	401.0M	401.0M	401.0M	401.0M	360.0M
Capital Reserve	190.0M	187.0M	179.0M	142.0M	4.6M
Surplus Reserve	55.5M	53.6M	53.6M	50.3M	27.6M
Retained Earnings	154.0M	138.0M	332.0M	352.0M	156.0M
Minority Equity	1.2M	-265,700	-190,100	1.8M	-70,300
Equity Attributable	869.0M	849.0M	965.0M	945.0M	549.0M
Total Equity	870.0M	849.0M	965.0M	947.0M	549.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	228.0M	224.0M	763.0M	588.0M	307.0M
Tax Refunds Received	12.9M	14.8M	5.6M	102,700	2.8M
Total Operating Cash Inflow	258.0M	260.0M	786.0M	613.0M	336.0M
Cash Paid For Goods	97.2M	103.0M	300.0M	136.0M	111.0M
Cash Paid To Employees	83.4M	118.0M	166.0M	94.8M	62.0M
Taxes Paid	3.3M	24.0M	54.2M	52.0M	23.5M
Total Operating Cash Outflow	224.0M	297.0M	634.0M	357.0M	272.0M
Operating Cash Flow	34.3M	-37.2M	153.0M	255.0M	63.8M
Total Investing Cash Inflow	762.0M	409.0M	874.0M	441.0M	814.0M
Total Investing Cash Outflow	1.1B	475.0M	1.1B	868.0M	888.0M
Investing Cash Flow	-348.0M	-66.2M	-190.0M	-427.0M	-73.8M
Cash From Borrowings	109.0M	392.0M	64.0M	--	22.0M
Dividends And Interest Paid	5.3M	12.9M	101.0M	18.0M	45.4M
Debt Repayments	10.2M	25.1M	2.6M	--	22.0M
Total Financing Cash Inflow	112.0M	392.0M	66.7M	196.0M	22.0M
Total Financing Cash Outflow	25.3M	59.1M	121.0M	55.1M	68.2M
Financing Cash Flow	87.1M	333.0M	-53.8M	141.0M	-46.2M
Net Change In Cash	-225.0M	235.0M	-92.0M	-35.0M	-66.5M
Ending Cash Balance	257.0M	482.0M	247.0M	339.0M	374.0M
Capex	174.0M	129.0M	177.0M	79.5M	82.8M